Key Cancer Biopsy Market Players:
- ANGLE plc
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- BD (Becton, Dickinson and Company)
- Biodesix (Integrated Diagnostics)
- Chronix Biomedical, Inc (Oncocyte Corporation )
- Devicor Medical Products, Inc.
- GRAIL, Inc.
- Hologic, Inc.
- Illumina, Inc.
- IZI Medical Products
- Lucence Health Inc.
- Myriad Genetics, Inc.
- Oncimmune Holdings PLC
- Personal Genome Diagnostics Inc.
- QIAGEN N.V.
Companies are adopting a wide range of strategies to remain competitive in the market. This includes development and innovations, majorly in tissue biopsies, liquid biopsies, and advanced molecular diagnostics. For instance, in September 2023, Mermaid Medical launched M∙Biopsy semi-automatic and fully automatic biopsy needles, for soft tissue biopsy solutions. Collaborations and partnerships with research institutions, diagnostic labs, and pharmaceutical companies are also common, allowing firms to expand their technological capabilities. Regulatory approvals are also explored strategically by these prominent players for obtaining certifications and meeting global standards.
Some of the prominent players in the market include:
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2026, the industry size of cancer biopsy is estimated at USD 31.92 billion.
Cancer Biopsy Market size was over USD 29.73 billion in 2025 and is poised to exceed USD 65.38 billion by 2035, witnessing over 8.2% CAGR during the forecast period i.e., between 2026-2035.
North America leads the Cancer Biopsy Market with a 42.7% share, supported by the presence of leading players and ongoing acquisitions to expand capabilities in cancer diagnostics and treatments, ensuring growth through 2035.
Key players in the market include BD (Becton, Dickinson and Company), Biodesix (Integrated Diagnostics), Chronix Biomedical, Inc. (Oncocyte Corporation).
